Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

TTI-101 and Pembrolizumab in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Trial Status: withdrawn

This phase I/II trial tests the safety, side effects, and best dose of STAT3 Inhibitor C-188-9 (TTI-101) and pembrolizumab for treating patients with head and neck squamous cell carcinoma that has come back after treatment (recurrent) or has spread from where it first started (primary site) to other places in the body (metastatic). TTI-101 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving TTI-101 in combination with pembrolizumab may be more effective in treating patients with recurrent or metastatic HNSCC than giving either treatment alone.